Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
Associação Brasileira de Psiquiatria
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/jspui/handle/123456789/25437 http://dx.doi.org/10.1590/S1516-44462011000300003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|